Clinical Trial Update: Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial assessing a triple combination of relatlimab, nivolumab, and ipilimumab in patients with asymptomatic and symptomatic melanoma brain metastases is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Relatlimab (relatlimab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Stanford University | Conditions: Melanoma, Brain Metastases | Phase 2 | Status: RECRUITING